Trial Profile
A Double-blind, Placebo Controlled, Randomised, Phase IIA Pharmacodynamic 4-way Cross-over Study to Estimate the Dose Response Relationship of AZD3355 on the Number of Reflux Episodes Assessed by Impedance/pH in Patients With GERD and a Partial Response to PPI Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Lesogaberan (Primary) ; Proton pump inhibitors
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 10 May 2011 Results presented at Digestive Disease Week 2011.
- 20 May 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.